What are the 2025 European Association for the Study of the Liver (EASL) Barcelona Clinic Liver Cancer (BCLC) guideline recommendations for the diagnosis, staging, and management of hepatocellular carcinoma?

2025 EASL BCLC Guidelines for Hepatocellular Carcinoma

Overview

The 2025 EASL Clinical Practice Guidelines represent the most current, evidence-based framework for managing hepatocellular carcinoma (HCC), maintaining the BCLC staging system as the global reference for prognosis prediction and treatment allocation while incorporating critical advances in systemic therapy, particularly immunotherapy combinations 1.

Staging System

The BCLC staging classification remains the cornerstone for treatment stratification, directly linking each stage to evidence-based first-line treatment options 1, 2. The 2025 update builds upon the 2022 BCLC revision 1, maintaining its prognostic capacity while embedding person-centered decision-making.

Key Staging Components:

• Tumor burden (size, number, vascular invasion)
• Liver function (Child-Pugh class, portal hypertension)
• Performance status (ECOG)
• Cancer-related symptoms

Diagnosis

Imaging Criteria:

• Contrast-enhanced CT or MRI serve as primary diagnostic modalities
• 18F-fluorocholine PET/CT improves tumor staging and treatment allocation compared to conventional imaging 1
• Standard 18F-FDG PET/CT has limited utility for intrahepatic HCC detection but helps identify extrahepatic metastases 1

Biomarkers:

• AFP, AFP-L3, and DCP are recommended for monitoring treatment response and predicting recurrence 1
• AFP-L3 and DCP strongly predict early recurrence after liver transplantation 1
• AFP serves as a surrogate biomarker for immunotherapy response, particularly with atezolizumab + bevacizumab 1

Treatment Recommendations by Stage

Very Early/Early Stage (BCLC 0/A)

Curative treatments are prioritized:

• Surgical resection for single tumors with preserved liver function
• Liver transplantation following appropriate selection criteria
• Ablation (radiofrequency or microwave) for small tumors not amenable to surgery

Modern hepatectomy achieves near-zero mortality in high-volume centers 1, making surgery the preferred option when technically feasible with adequate liver reserve.

Intermediate Stage (BCLC B)

This stage demonstrates significant heterogeneity requiring subclassification 1:

• Transarterial chemoembolization (TACE) remains first-line for most patients
• Prognostic scores (HAP, ART, ALBI) guide retreatment decisions and predict outcomes 1
• Systemic therapy (lenvatinib or atezolizumab + bevacizumab) should be considered for patients beyond up-to-seven criteria or those unsuitable for TACE 1

Critical decision point: Assess liver function during repeated TACE procedures; deteriorating hepatic function signals need to transition to systemic therapy 1.

Advanced Stage (BCLC C)

First-line systemic therapy options (in order of evidence strength):

1. Atezolizumab + bevacizumab - preferred first-line based on IMbrave150 trial showing superior overall survival [1, @10@]

   • Contraindications: active bleeding risk, untreated varices
   • AFP serves as predictive biomarker 1

2. Tremelimumab + durvalumab (STRIDE regimen) - alternative first-line option with 4-year survival data from HIMALAYA trial [1,3, @11@]

3. Lenvatinib - non-inferior to sorafenib, option when immunotherapy contraindicated 1, 4

4. Sorafenib - established standard with long-term data 1, 2

Second-line options after progression:

• Ramucirumab for patients with AFP ≥400 ng/mL (REACH-2 trial) [1, @12@]
• Other TKIs (cabozantinib, regorafenib) based on prior therapy

Radioembolization Considerations

Selective internal radiotherapy (SIRT) with Y-90 microspheres did not demonstrate survival benefit over sorafenib in SARAH and SIRveNIB trials 1, limiting its routine recommendation. However, real-world data suggest benefit in selected patients 1.

Clinical Decision-Making Framework

CUSE Framework Integration

The 2025 update introduces the CUSE framework (Complexity, Uncertainty, Subjectivity, Emotion) for structured multidisciplinary decision-making 2:

1. Define therapeutic goal: survival vs. tumor control vs. quality of life
2. Grade each treatment option: note evidence strength and gaps
3. Align choices with comorbidities, feasibility, oncologic risk, and patient values
4. Select plan with regular reassessment as new information emerges

This framework explicitly addresses evidence gaps and uncertainty, moving beyond simple stage-based algorithms to incorporate biological, psychosocial, and contextual factors affecting morbidity and patient vulnerability 2.

Prognostic Scores

Multiple validated scores guide treatment decisions:

• CRAFITY score: predicts outcomes with immunotherapy 1
• HAP/ART scores: guide TACE retreatment decisions 1
• ALBI grade: assesses liver function during treatment 1
• Prognostic Nutritional Index: predicts survival with atezolizumab + bevacizumab 1

Key Practice Points

Common pitfalls to avoid:

• Continuing TACE beyond hepatic function deterioration
• Missing contraindications to bevacizumab (untreated varices, bleeding risk)
• Failing to assess AFP levels before selecting second-line therapy (ramucirumab requires AFP ≥400 ng/mL)
• Not incorporating patient goals and values into treatment selection

The 2025 guidelines emphasize that treatment decisions must balance evidence-based recommendations with individual patient context, using structured frameworks like CUSE to navigate complexity and uncertainty in real-world practice 2.